WP 05 Management of Data and Biological Samples
The overall goal of this work package is to support development of translational approaches for ASD treatment by storing and processing biological samples ascertained by other work packages, and by building and maintaining a data management infrastructure. The specific objectives are to:
- Facilitate collaboration by establishing a repository of samples, phenotypic and ?omics data acquired as part of WP1, WP 2, WP 3 and WP 4
- Analyse existing samples to identify predictive and prognostic marker sets, and characterise genetic mechanisms associated with ASD and autism-related behavioural traits.
- Enable efficient and rapid information exchange within and between different work packages by establishing a data sharing platform.
- Collaborate with other international biobank resources, including AGRE and SFARI (SSC) with the aim of harmonizing SOPs and phenotype descriptions and providing unified access to data.
- Develop common regulatory and ethics applications, which allow patient recall and maximize sample and data flow across sites in current and future studies.
Academic Lead: Dr. Ugis Sarkans, European Molecular Biology Laboratory, UK and Germany
EFPIA Lead: Dr. Philip Szekeres, Eli Lilly and Company Ltd.,UK
"Bioresource" Lead: Prof. Dr. Gunter Schumann, King's College London, UK
- European Molecular Biology Laboratory
- Eli Lilly and Company Ltd.
- King's College London
- F. Hoffmann- La Roche
- Autism Speaks
- Commissariat ΰ l'Energie Atomique et Aux Alternatives
- A repository of samples will be established, facilitating idendification of markers of disease risk, severity and therapeutic response.
- Genomic mechanisms underlying ASD will be further characterized.
- A data sharing platform will be established, enabling data collection, integration, management, and access.
- Operating practices and information will be integrated with comparable projects in U.S., in particular, NDAR and Autism Speaks.